Daniel R Wahl, MD, PhD
Department of Radiation Oncology
1500 East Medical Center Drive, UH B2C490 SPC 5010
Ann Arbor, MI 48109-5010
Manage Your Profile
About
Dr. Wahl is a physician scientist at the University of Michigan specializing in cancers of the central nervous system. His research focuses on the development of new treatment strategies for brain tumors and his laboratory group is especially interested in interactions between radiation and abnormal metabolism in glioblastoma. In the clinic, he cares for a wide variety of patients with both malignant and benign tumors of the central nervous system.
Links
Wahl Lab Personal page on department website
Center Memberships
-
Center MemberRogel Cancer Center
-
Center MemberTaubman Institute
Research Overview
Dr. Wahl's research focuses on developing strategies to overcome treatment resistance in aggressive brain tumors. He has a particular interest in understanding and interrupting the links between altered metabolism and radiation resistance in glioblastoma.
Recent Publications
-
Scott AJ, Lyssiotis CA, Wahl DR. Nat Metab, 2026 Apr 29;Journal ArticleBrain cells refine nitrogen choice with maturity.
DOI:10.1038/s42255-026-01519-7 PMID: 42056504 -
Syed S, Tripathy A, Ji S, Alomary Y, de la Nava Martin D, Mota M, Chakravarthy R, Huang D-L, Wang Z, Li Z, Zhang Q, Lawrence T, Wahl D, Koschmann C, Venneti S, Rehemtulla A, Al-Holou W. Neurosurgery, 2026 Mar 17; 72 (Supplement_1): 109 - 109.Journal Article393 THY1: A Therapeutically Targetable Mediator of Treatment Resistance in H3K27M Pediatric Tumors
DOI:10.1227/neu.0000000000003964_393 -
Wahl D. 2026 May 20;PresentationMeasuring and targeting altered metabolism in brain cancer
-
Hong C-C, Wahl D, Bogler O. 2026 May 20;PresentationWhat Reviewers Look for in Your RPG Application: Perspectives from Reviewers
-
Torres M, Lu Y, Pederson B, Wang H, Gretzinger A, Lin L, Hwang J, Chen X, Rupp AC, Tomlinson AJ, Scott AJ, Zhao Z, Wahl DR, Myers M, Lyssiotis CA, Qi L. J Clin Invest, 2026 Feb 19;Journal ArticleNeuronal SEL1L-HRD1 ER-associated degradation is essential for motor function and survival in mice.
DOI:10.1172/JCI196819 PMID: 41712288 -
Meghdadi B, Al-Holou WN, Scott AJ, Mittal A, Liang N, Sravya P, Achreja A, O’Brien A, Do K, Wu Z, Feng J, Qi NR, Tarnal V, Venneti S, Miller CR, Sarkaria JN, Zhou W, Lawrence TS, Lyssiotis CA, Wahl DR, Nagrath D. Cell Metabolism, 2026 Jan 6; 38 (1): 228 - 246.e17.Journal ArticleDigital twins for in vivo metabolic flux estimations in patients with brain cancer
DOI:10.1016/j.cmet.2025.10.022 PMID: 41330373 -
Scott AJ, Liang N, Al-Holou WN, Xu J, O'Brien A, Lin A, Pareek V, Sha Z, Zhao Z, Yang JZ, Yang A, Kothari AU, Wilder-Romans K, Wu Z, Feng J, Korimerla N, Elaimy A, Palavalasa S, Chen J, Wang L, Zhang L, Andren AC, Sajjakulnukit P, Marini B, Heth JA, Morgan MA, Lawrence TS, Benkovic SJ, Nagrath D, Chandrasekaran S, Qi NR, Sun D, Wen B, Pai MP, Clarke N, Suresh K, Umemura Y, Lyssiotis CA, Zhou W, Wahl DR. 2025 Nov 13;PreprintAdaptive nuclear GTP synthesis promotes glioblastoma treatment resistance and is a targetable vulnerability in patients.
DOI:10.1101/2025.11.11.25340023 PMID: 41292630 -
Meghdadi B, Al-Holou W, Scott A, Mittal A, Liang N, Palavalasa S, Achreja A, Qi N, O’Brien A, Tarnal V, Zhou W, Lawrence T, Lyssiotis C, Wahl D, Nagrath D. Neuro-Oncology, 2025 Nov 12; 27 (Supplement_5): v441 - v441.Journal ArticleTMET-57. Integrating scRNA-seq and13C-tracing delineates metabolic heterogeneity in the glioblastoma tumor microenvironment
DOI:10.1093/neuonc/noaf201.1748 PMID: PMC12601269
Featured News & Stories
Brain cancer digital twin predicts treatment outcomes
Dietary changes could provide a therapeutic avenue for brain cancer